China

China is advocating reforms to health insurance, particularly the wider use of commercial schemes, for reasons to support innovative drug development.

A few months after a positive Phase III trial readout, Henlius has filed an application for its Organon-partnered Perjeta biosimilar in its domestic Chinese market.

The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.

China's Belief BioMed presented promising new Phase III results at ASH for its AAV gene therapy for hemophilia B, although the wider China CGT space continues to be dominated by oncology.

In addition to C-Ray Therapeutics’ $100m-plus series A+ round, Allink Biotherapeutics and IMPACT Therapeutics closed VC/PE-backed financing deals worth $42m and $34m, respectively. Other Chinese biotechs also sealed smaller deals.

Chinese biosimilars developer Henlius has celebrated its first shipment to the US, opening up a potentially lucrative market for the firm via local marketing partner Accord.

China’s fresh approval of a sublingual form of Simcere's edaravone/dexborneol brain cytoprotective agent for acute ischemic stroke is paving the way for an international Phase III study in this indication.

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.

The pharma industry arguably suffered none of the possible downside risks during the first Trump Administration, but its relationship with Biden could not have been much worse. And while sponsors may hope a Trump return could improve their fortunes, having Robert F. Kennedy Jr. supervising the FDA is likely not the prescription they prefer.

Roche's blockbuster ophthalmic drug set for China reimbursement list inclusion in three indications and shows positive interim results in PCV.